Exploring Recent Developments in the Treatment of Patients with HR+ Metastatic Breast Cancer
A select group oncology experts met to engage in a virtual discussion workshop moderated by oncologist Erika Hamilton, MD. The overall objectives were to review recent data on therapeutic advances in HR+ BC. This article summarizes data from recent trials in early HR+ and TNBC; HR+ metastatic BC, focusing on use of CDK4/6 inhibitors in the first line and second line and beyond; and promising new endocrine therapies that may represent the future direction of HR+ cancer treatment.
Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.
Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.
Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.
